Get started
Author

Victoria Marie Garbitt

Observed names: V M Garbitt, Victoria Garbitt, Victoria M Garbitt, Victoria M. Garbitt, Victoria M. Garbitt (14870384)
ORCID: 0009-0003-0535-6508
Observed ORCID: 0009-0003-0535-6508
OpenAlex ID: A5040907492
Clonal competition with alternating dominance in multiple myeloma
2012 · Jonathan J. Keats, Marta Chesi, et al. · Blood · 637
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
2014 · M Affer, M Chesi, et al. · Leukemia · 268
Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression
2018 · Arianna Calcinotto, Arianna Brevi, et al. · Nature Communications · 223
PDF
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
2012 · Marta Chesi, Geoffrey M. Matthews, et al. · Blood · 214
IAP antagonists induce anti-tumor immunity in multiple myeloma
2016 · Marta Chesi, Noweeda N Mirza, et al. · Nature Medicine · 171
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
2013 · J Schmidt, E Braggio, et al. · Leukemia · 165
SIK1 Couples LKB1 to p53-Dependent Anoikis and Suppresses Metastasis
2009 · Hailing Cheng, Pixu Liu, et al. · Science Signaling · 159
Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy
2021 · Erin W. Meermeier, Seth J. Welsh, et al. · Blood Cancer Discovery · 112
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
2023 · Seth J. Welsh, Benjamin G. Barwick, et al. · Blood Cancer Discovery · 42
Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression
2020 · Marta Chesi, Caleb K. Stein, et al. · Blood Cancer Discovery · 40
Identification of Novel Therapeutic Targets in the Clinically Predictive Vk*MYC Mouse Model of Multiple Myeloma
2014 · Marta Chesi, Victoria Garbitt, et al. · Blood · 6
A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma
2018 · Danielle C Croucher, Marta Chesi, et al. · Blood · 3
IAP Antagonists Are a Novel Class Of Immunomodulators That Induce Complete Response In Vk*MYC Myeloma By Stimulating Plasmacytoid Dendritic Cells To Secrete IFNa
2013 · Marta Chesi, Victoria Garbitt, et al. · Blood · 3
Genome Wide Studies in Multiple Myeloma Identify XPO1/CRM-1 As a Critical Target Validated Using the Selective Inhibitor of Nuclear Export (SINE) KPT-276
2012 · Jessica Schmidt, Esteban Braggio, et al. · Blood · 2
The Vk*MYC Mouse Model of Myeloma Identifies Successful Combination Therapies for the Treatment of Bortezomib Refractory Myeloma Patients
2010 · Marta Chesi, Stephen Palmer, et al. · Blood · 2
P-177 Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma (MM)
2023 · Seth Welsh, Benjamin Barwick, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma
2021 · Seth Welsh, Daniel Riggs, et al. · Blood · 1
Abstract 3015: IMiDs and BET inhibitors target distinct pathways of MYC dysregulation by super-enhancers in multiple myeloma
2019 · Daniel L. Riggs, Camille Herzog, et al. · Cancer Research · 1
Mir-15a/16-1 Haploinsufficiency Contributes To Myeloma Progression
2013 · Marta Chesi, Victoria Garbitt, et al. · Blood · 1
Data from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
2024 · Seth J. Welsh, Benjamin G. Barwick, et al.
Supplementary Data 1 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
2024 · Seth J. Welsh, Benjamin G. Barwick, et al.
Supplementary Data 1 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
2024 · Seth J. Welsh, Benjamin G. Barwick, et al.
Supplementary Data 5 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
2024 · Seth J. Welsh, Benjamin G. Barwick, et al.
Supplementary Figures S1-S11 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
2024 · Seth J. Welsh, Benjamin G. Barwick, et al.
Supplementary Data 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
2024 · Seth J. Welsh, Benjamin G. Barwick, et al.
Works count: 71
Citation count: 2,051
H-index: 10
I10-index: 10
Year
Topic
Type